Canadian Branded Drug Makers Miss R&D Target

Law360, New York (October 26, 2004, 12:00 AM EDT) -- Canadian branded drug makers are spending less on research and development than they pledged to under a deal to get passage of stricter patent laws more than a decade ago, a new survey has found.

In 1987 and 1993, Prime Minister Brian Mulroney's conservative government agreed to overhaul Canada’s drug patent laws in favor of the branded drug industry by ending the process of compulsory licensing that had allowed generic drug makers to produce lower-cost versions of a patented medicines in return for a small royalty....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.